Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
Publication
, Journal Article
Mor, A; Bingham, CO; Barisoni, L; Lydon, E; Belmont, HM
Published in: The Journal of rheumatology
April 2005
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
Duke Scholars
Published In
The Journal of rheumatology
EISSN
1499-2752
ISSN
0315-162X
Publication Date
April 2005
Volume
32
Issue
4
Start / End Page
740 / 743
Related Subject Headings
- Withholding Treatment
- Vasculitis, Leukocytoclastic, Cutaneous
- Recombinant Fusion Proteins
- Receptors, Tumor Necrosis Factor
- Lupus Nephritis
- Immunoglobulin G
- Immunocompromised Host
- Humans
- Female
- Etanercept
Citation
APA
Chicago
ICMJE
MLA
NLM
Mor, A., Bingham, C. O., Barisoni, L., Lydon, E., & Belmont, H. M. (2005). Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of Rheumatology, 32(4), 740–743.
Mor, Adam, Clifton O. Bingham, Laura Barisoni, Eileen Lydon, and H Michael Belmont. “Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.” The Journal of Rheumatology 32, no. 4 (April 2005): 740–43.
Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of rheumatology. 2005 Apr;32(4):740–3.
Mor, Adam, et al. “Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.” The Journal of Rheumatology, vol. 32, no. 4, Apr. 2005, pp. 740–43.
Mor A, Bingham CO, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. The Journal of rheumatology. 2005 Apr;32(4):740–743.
Published In
The Journal of rheumatology
EISSN
1499-2752
ISSN
0315-162X
Publication Date
April 2005
Volume
32
Issue
4
Start / End Page
740 / 743
Related Subject Headings
- Withholding Treatment
- Vasculitis, Leukocytoclastic, Cutaneous
- Recombinant Fusion Proteins
- Receptors, Tumor Necrosis Factor
- Lupus Nephritis
- Immunoglobulin G
- Immunocompromised Host
- Humans
- Female
- Etanercept